/term/price-to-ffo/SHSE:603520 Zhejiang Starry Pharmaceutical Co (SHSE:603520) Price-to-Fu
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Starry Pharmaceutical Co Ltd (SHSE:603520) » Definitions » Price-to-Funds-From-Operations

Zhejiang Starry Pharmaceutical Co (SHSE:603520) Price-to-Funds-From-Operations : (As of Jun. 20, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Zhejiang Starry Pharmaceutical Co Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.

Zhejiang Starry Pharmaceutical Co (SHSE:603520) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Starry Pharmaceutical Co Ltd (SHSE:603520) » Definitions » Price-to-Funds-From-Operations
Comparable Companies
SHSE:688247 SZSE:300485 SZSE:300110 SZSE:002644 SHSE:600488 SZSE:002393 SZSE:300194 SZSE:300401 SZSE:300636 SHSE:603998 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
No.1 Sitali Avenue, Modern Industrial Gathering District, Zhejiang Province, Xianju County, Taizhou City, CHN, 317306
Website
http://www.starrypharm.com
Zhejiang Starry Pharmaceutical Co Ltd is engaged in R&D, manufacture and marketing of active ingredient and intermediate X-CT non-ionic contrast agent series and Fluoroquinolones series.
Executives
Hu Jin Sheng Director